| Business Summary | | IRIDEX
Corporation
is
a
worldwide
provider
of
semiconductor-based
laser
systems
used
to
treat
eye
diseases
in
ophthalmology
and
skin
lesions
in
dermatology.
The
Company's
products
are
sold
in
the
United
States
predominantly
through
a
direct
sales
force
and
internationally
through
54
independent
distributors
into
74
countries.
The
Company's
ophthalmology
products
treat
eye
diseases,
including
the
three
leading
causes
of
irreversible
blindness.
The
current
family
of
ophthalmology
laser
systems
includes
the
IRIS
Medical
OcuLight
SL,
OcuLight
SLx,
OcuLight
GL
and
OcuLight
GLx
Laser
Photocoagulation
systems
(each
an
OcuLight
System).
The
Company's
dermatology
products,
including
the
IRIDERM
DioLite
532
Laser
System,
treat
skin
diseases,
primarily
vascular
and
pigmented
lesions.
Each
ophthalmic
and
dermatologic
system
consists
of
a
small,
portable
laser
console
and
interchangeable
delivery
devices,
primarily
for
hospital
and
office-based
use
by
ophthalmologists
and
dermatologists. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Iridex
provides
semiconductor
based
laser
systems
used
to
treat
eye
diseases,
including
the
three
leading
causes
of
irreversible
blindness
(macular
degeneration,
diabetic
retinopathy
and
glaucoma).
For
the
six
months
ended
6/01,
revenues
fell
24%
to
$12.8
million.
Net
loss
from
con't
operations
totalled
$913
thousand
vs.
an
income
of
$1.4
million.
Results
reflect
decreased
unit
volumes
due
to
a
decreased
consumer
base
for
OcuLight
GLx,
along
with
reduced
margins. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| John Nehra, 52 Chairman | -- | -- | Theodore Boutacoff, 54 Pres,
Director and CEO | $218K | -- | Robert Kamenski, 46 CFO
and VP of Admin. | 151K | $9.6K | Eduardo Arias, 56 Sr.
VP of Worldwide Sales | 155K | -- | Timothy Powers, 39 VP
of Operations | 154K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|